PYC Shareholders Approve Director Rights, But CEO Options Draw More Opposition
PYC: $1.91 +0.52% · MC: $1.9B
PYC Therapeutics shareholders passed all resolutions at the 2026 AGM, including awards of restricted and performance rights to CEO Rohan Hockings, which received strong support. Approval for up to 1.5 million options for Hockings drew more opposition, with about 28% of votes cast against; options for Professor Ian Constable received about 35% opposition.

Comments